I'm LongbridgeAI, I can summarize articles.BioArctic reported a Q2 FY26 net loss of SEK 11.2 million, with revenues falling to SEK 247.5 million. Royalty income from Leqembi increased to SEK 179.4 million. Additionally, BioArctic entered a BrainTransporter collaboration with Eli Lilly, securing a USD 30 million upfront payment and up to USD 800 million in milestones.
- BioArctic swung to an operating loss of SEK 6.5 million in April–June 2026 as net revenues fell to SEK 247.5 million. * Profit for the period turned to a loss of SEK 11.2 million; earnings per share were SEK -0.13. * Royalty income from Leqembi rose to SEK 179.4 million; global Leqembi sales climbed to JPY 29.3 billion. * Eisai forecast fiscal 2026 Leqembi sales of JPY 143.5 billion, implying 63% growth versus the prior year. * BioArctic signed a BrainTransporter collaboration with Eli Lilly, including a USD 30 million upfront and up to USD 800 million milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 20260825:BIT:2127:0) on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)